Antitumor Activity of Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Single-arm, Multicenter Study
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Toripalimab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 26 Feb 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2026.
- 26 Feb 2024 Planned primary completion date changed from 1 Mar 2023 to 31 Dec 2025.
- 26 Feb 2024 Status changed from not yet recruiting to recruiting.